Abstract 393P
Background
Pulmonary mucinous epidermoid carcinoma (PMEC) is malignant and extremely rare. With only few case reports or small case series are reported, the prognosis of PMEC is not fully understood. In this study, we aimed to evaluate the prognostic factors of PMEC and to establish a prognostic nomogram model to predict its cancer-specific survival (CSS).
Methods
Within the Surveillance, Epidemiology, and End Results (SEER) Database from its inception to December 31, 2016, patients diagnosed with PMEC were retrospectively identified. Kaplan–Meier analysis and Cox regression were performed to evaluate the CSS stratified by different covariates. A predictive model of nomograms was conducted and the Concordance index (C-index) and calibration curves were used to validate the model.
Results
A total of 585 PMEC patients are identified. The 5-, 10-, and 20-year CSS of stage I-II PMEC were 96.0%, 91.4%, and 88.9%, respectively. The 1-, 3-, 5-, and 10-year CSS of stage III-IV PMEC were 56.5%, 39.45%, 32.1%, 29.4%, respectively. The results of survival curves showed that patients with older ages, larger tumor sizes, bilateral tumors, poorer differentiation and higher stage of T, N and M aligned with poorer prognosis. Surgical treatment significantly improved the patients’ CSS (P < 0.001). But combined therapy didn't present better CSS results than surgery alone did. The multivariate COX results revealed that the covariates of age, bilateral tumor, tumor sizes, pathological differentiation grade, T stage, N stage, M stage and therapy were independent prognosis factors for PMEC. These factors were used to construct a nomogram. The C-index of the nomogram was 0.921. The calibration curve showed that favorable consistency between the predicted PMEC CSS and the actual observation. Validation of the nomogram was conducted with the validation cohort. The C-index of validation was 0.968, and the calibration curve showed favorable consistency.
Conclusions
Age, bilateral tumor, tumor sizes, pathological differentiation grade, T stage, N stage, M stage, and therapy were independent prognosis factors of PMEC patients. A nomogram on predicting the CSS of PMEC was first built and validated, showing its potential value in practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lingxiao Qiu.
Funding
The National Natural Science Foundation of China (No.81874042).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Real world outcomes in elderly women with HER2-positive advanced breast cancer
Presenter: Nicole Evans
Session: e-Poster Display Session
52P - Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study)
Presenter: Yookija Kang
Session: e-Poster Display Session
53P - Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2- metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression
Presenter: Indunil Weerasena
Session: e-Poster Display Session
54P - Platinum-based chemotherapy in advanced breast cancer (ABC): Real-world outcome from a tertiary cancer centre in India
Presenter: Indhuja Vijesh
Session: e-Poster Display Session
55P - Eribulin in heavily pretreated metastatic breast cancer: A real-world data from India
Presenter: Tanmoy Mandal
Session: e-Poster Display Session
56P - Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
Presenter: Yiqi Yang
Session: e-Poster Display Session
57P - Therapeutic vulnerability of malignant phyllodes tumour to pazopanib identified through a novel patient-derived xenograft and cell line model
Presenter: Dave Ng
Session: e-Poster Display Session
58P - Survival benefit of local treatments in breast cancer with lung metastasis: Results from a large retrospective study
Presenter: Yimeng Chen
Session: e-Poster Display Session
59P - The impact of site of metastasis on overall survival in indigenous and non-indigenous patients of Western Australia with breast cancer
Presenter: Azim Khan
Session: e-Poster Display Session
60P - Risk factors of bone metastasis and skeletal-related events in high-risk breast cancer patients
Presenter: Sumadi Lukman Anwar
Session: e-Poster Display Session